DelveInsight’s PCSK9 Inhibitors market report provides an in-depth understanding of the PCSK9 Inhibitors, historical and forecasted epidemiology, as well as PCSK9 Inhibitors market trends in the 7MM. The PCSK9 Inhibitors market report also covers current treatment practices, emerging drugs, PCSK9 Inhibitors market share of individual therapies.
Some of the Key Highlights from the PCSK9 Inhibitors Market Report
According to the National Organization for Rare Disorders (NORD), Familial Hypercholesterolemia is one of the most common genetic diseases, affecting approximately one in every 250 people.
As per DelveInsight estimates, the Familial Hypercholesterolemia diagnosed cases were 322,852 in the US in 2020, which is further expected to increase by 2030.
As per the estimates, the total Familial Hypercholesterolemia prevalent cases were 1,270,635 in EU5 in 2020.
The leading players active in the PCSK9 Inhibitors market include LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, and others.
Key PCSK9 Inhibitors therapies in the pipeline include LIB003 (Lerodalcibep), AZD8233 (ION449), CIVI 007, and others.
AZD8233 (ION449), formerly IONIS-AZ4-2.5-LRx, is an investigational ligand-conjugated antisense medicine. As part of a collaboration between Ionis Pharmaceuticals and AstraZeneca, AstraZeneca is developing ION449.
CiVi 007 is a long-acting, third-generation PCSK9 in development by CiVi Biopharma to treat hypercholesterolemia and prevent atherosclerotic cardiovascular disease (ASCVD).
The PCSK9 Inhibitors market size is anticipated to increase with a CAGR of 16.5% by 2030.
Have queries? Request for the sample @ PCSK9 Inhibitors Market Outlook
PCSK9 Inhibitors Overview
Proprotein convertase subtilisin/Kexin type 9 (PCSK9) regulates the degradation of low-density lipoprotein (LDL) receptors, which is important in cholesterol metabolism. It promotes the degradation of low-density lipoprotein (LDL) receptors, reducing the clearance of circulating LDL particles.
PCSK9 Inhibitors Epidemiology Segmentation
The PCSK9 Inhibitors report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
Familial Hypercholesterolemia Total Prevalent Cases
Familial Hypercholesterolemia Total Diagnosed Cases
Familial Hypercholesterolemia Type-Specific Cases
Familial Hypercholesterolemia Age Group-Specific Cases
Familial Hypercholesterolemia Mutation-Specific Cases
PCSK9 Inhibitors Risk Factors-Specific Cases in Prophylactic/Preventive Setting
PCSK9 Inhibitors Total Treated Cases
PCSK9 Inhibitors Treatment Landscape
There are currently two PCSK9 inhibitors available in the United States: Alirocumab and Evolocumab, which the FDA has approved for adult patients to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalisation in adults with established cardiovascular disease as an adjunct to diet, alone or in combination with other lipid-lowering therapies, for the treatment of adults with primary hyperlipidemia (including HeFH) to reduce LDL-cholesterol.
PCSK9 Inhibitors Market Outlook
The PCSK9 Inhibitors market size is anticipated to increase with a CAGR of 16.5% by 2030. The PCSK9i market is expected to grow significantly due to the use of PCSK9 inhibitors in statin-intolerant patients, promising future PCSK9 inhibition strategies, implications of PCSK9 inhibitors in broader therapy areas, and PCSK9 inhibition in a prophylactic setting, which can reduce CVD burden.
PCSK9 Inhibitors Pipeline Therapies and Key Companies
LIB003 (Lerodalcibep): LIB Therapeutics
AZD8233 (ION449): Ionis Pharmaceuticals/AstraZeneca
CIVI 007: CiVi Biopharma
For complete information on the emerging therapies, visit @ PCSK9 Inhibitors Drugs
PCSK9 Inhibitors Market Drivers
Use of PCSK9 inhibitors in statin-intolerant patients
PCSK9 inhibition in a prophylactic setting can relieve the CVD burden
Promising future strategies of PCSK9 inhibition
Implications of PCSK9 inhibitors in broader therapy areas
PCSK9 Inhibitors Market Barriers
Premium pricing of the drugs has resulted in low commercial uptake
Lack of long-term safety and efficacy data
Commercial payer actions affect market access and sales of Repatha
Strict reimbursement scenario in the 7MM
Use of off-label therapies and generics
Scope for the Report
Coverage: 7MM (the US, EU5 (the UK, Germany, Italy, Spain, and France) and Japan)
Study Period: 2018-30
PCSK9 Inhibitors Key Companies: LIB Therapeutics, Ionis Pharmaceuticals, AstraZeneca, CiVi Biopharma, among others.
PCSK9 Inhibitors Key Pipeline Therapies: LIB003 (Lerodalcibep), AZD8233 (ION449), CIVI 007, and others.
PCSK9 Inhibitors Segmentation: By Geography, By PCSK9 Inhibitors therapies
Analysis: Comparative and conjoint analysis of PCSK9 Inhibitors emerging therapies
Tools Used: SWOT Analysis
Case Studies
KOL’s Views
Analyst’s Views
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
4.
PCSK9 Inhibitors Market Overview at a Glance
5.
Executive Summary of PCSK9 Inhibitors (PCSK9i)
6.
PCSK9 Inhibitors Epidemiology and Market Methodology
7.
PCSK9 Inhibitors (PCSK9i) Background and Overview
8.
PCSK9 Inhibitors Guidelines
9.
PCSK9 Inhibitors Epidemiology and Patient Population
10.
PCSK9 Inhibitors Patient Journey
11.
Key Endpoints in PCSK9 inhibitor Clinical Trials
12.
PCSK9 Inhibitors Marketed Drugs
13.
PCSK9 Inhibitors Emerging Therapies
14.
PCSK9 inhibitors: 7 Major Market Analysis
15.
PCSK9 Inhibitors Market Access and Reimbursement
16.
KOL Views
17.
18.
19.
SWOT Analysis
20.
PCSK9 Inhibitors Unmet Needs
21.
Appendix
22.
DelveInsight Capabilities
23.
Disclaimer
24.
About DelveInsight
Get in touch with our business executive for Healthcare Due Diligence Services
Related Reports
Familial Hypercholesterolemia Market
Get a comprehensive analysis of Familial Hypercholesterolemia pipeline therapies and key companies such as Sanofi, Regeneron Pharmaceuticals, Amgen, Esperion Therapeutics, Regeneron Pharmaceuticals, Novartis, among others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Sandeep JoshiEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: www.delveinsight.com/